Penumbra has recently received FDA approval and CE mark for its THUNDERBOLT system, the first computer-assisted vacuum therapy (CAVT) for stroke. Having recently reclaimed its US peripheral thrombectomy lead via the Lightning Bolt series, the California-based company faces a distinct challenge in translating this momentum into the neurovascular sector, where unique anatomy, higher risks, and stringent regulatory oversight impose much higher standards, according to GlobalData, a leading intelligence and productivity platform.
This development comes as aspiration catheters have grown markedly in neuro thrombectomy procedures over recent years, mirroring trends in peripheral vascular treatment. THUNDERBOLT combines modulated aspiration, an automated control of suction, with real-time clot detection.
Ashley Clarke, Senior Medical Analyst at GlobalData, comments: “THUNDERBOLT’s main competitor, Imperative Care’s Continuous Dual Aspiration Technique, relies on manual aspiration modulation, whereas THUNDERBOLT automatically adjusts suction in response to clot engagement. This difference may improve procedural consistency and potentially reduce risks in neurovascular interventions.”
Penumbra’s thrombectomy revenues in the US rose from about $677 million in 2023 to nearly $1.09 billion in 2025, reflecting the strength of its Lightning Bolt product line. This revenue growth has enabled Penumbra to close the gap with Stryker in the peripheral thrombectomy catheter segment.
Over that same time, aspiration catheter usage in neuro has also risen, driven by physician preference for less invasive tools and faster procedures, which may lead to the quick adoption of devices like THUNDERBOLT.
Clarke adds: “Peripheral vascular thrombectomy and neurovascular thrombectomy differ in vessel size, anatomical complexity and risk. Peripheral procedures have benefited rapidly from the simpler anatomy and lower risk of hidden complications associated with Lightning’s design. Neurovascular adoption will require robust neuro-specific clinical evidence and training programs for neurosurgeons and interventionalists to achieve similar success. Penumbra’s leadership in neurovascular care, supported by its peripheral gains, gives it practical expertise to excel with the first neuro CAVT thrombectomy device.”
The device is expected to ship with Penumbra’s established RED series catheters, combining familiar catheter design with automated aspiration features.
Additionally, Boston Scientific’s acquisition of Penumbra in January 2026 for $14.5 billion gives Penumbra additional commercial scale and regulatory support essential for broader rollout of THUNDERBOLT. What remains essential is rigorous neuro-validated outcome data for this and any future computer-assisted therapies.
Clarke concludes: “If THUNDERBOLT meets expected outcomes in neurovascular practice, Penumbra seems positioned to consolidate its leadership across aspiration thrombectomy. Peripheral gains show it can secure share when device performance, user acceptance, and commercialization align. In the neuro setting success will depend on how quickly clinicians accept CAVT under constrained procedural windows and regulatory oversight. Given its current strength over Imperative Care, and recent resource gains, Penumbra has good prospects to maintain, and possibly extend, its market lead.”
